Biocryst Pharmaceuticals (BCRX) EBIT Margin Growth (1y) (2011 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) EBIT Margin Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 602.00 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -16,814.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -143.00 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 78.00 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1,135.00 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 7,666.00 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 2,002.00 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -2,881.00 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -1.23 Mn |
| 10 | Biocryst Pharmaceuticals | 2.29 Bn | 1.94 Bn | 214.41 Mn | 2,688.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,688.00 |
| Mar 31, 2026 | -46,314.00 |
| Dec 31, 2025 | 3.68 Mn |
| Sep 30, 2025 | 1,199.00 |
| Jun 30, 2025 | 1,022.00 |
| Mar 31, 2025 | 3,020.00 |
| Dec 31, 2024 | 4,226.00 |
| Sep 30, 2024 | 2,031.00 |
| Jun 30, 2024 | 3,311.00 |
| Mar 31, 2024 | 2,570.00 |
| Dec 31, 2023 | 1,254.00 |
| Sep 30, 2023 | 926.00 |
| Jun 30, 2023 | 2,789.00 |
| Mar 31, 2023 | 5,875.00 |
| Dec 31, 2022 | 5,242.00 |
| Sep 30, 2022 | 8,575.00 |
| Jun 30, 2022 | 623.00 |
| Mar 31, 2022 | 16,950.00 |
| Dec 31, 2021 | 119,426.00 |
| Sep 30, 2021 | 59,370.00 |